Navigation Links
GW Pharmaceuticals plc Announces the Closing of its Initial Public Offering on the Nasdaq Global Market
Date:5/8/2013

l programs expected to enter Phase 1 and Phase 2 clinical trials in the next 12 months. For further information, please visit www.gwpharm.com

Forward-looking statements

This news release may contain forward-looking statements that reflect GWs current expectations regarding future events.  Forward-looking statements involve risks and uncertainties.  Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including its most recent Form F-1. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

For readers in the European Economic Area

In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and directed at qualified investors in that Member State within the meaning of the Prospectus Directive. The term "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant Member State), together with any relevant implementing measure in the relevant Member State.

For readers in the United Kingdom

This commu
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... SAN DIEGO, April 30, 2015  Tandem Diabetes Care ® ... and manufacturer of the t:slim ® and t:flex™ Insulin ... March 31, 2015. In comparing the first ... , Sales grew 53 percent to $12.3 million from $8.1 ... 2,487 pumps from 1,723 pumps "Our investment in ...
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended March 31, 2015 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:4/30/2015)... (Nasdaq: DRRX ) announced today financial results for ... million and net loss was $4.9 million for the ... total revenues of $6.3 million and net loss of ... 2014.At March 31, 2015, we had cash and investments ... $34.9 million at December 31, 2014.  Subsequent to quarter-end, ...
Breaking Medicine Technology:Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
... 2012  At the 2012 American Association of Neurological ... the Miami Beach Convention Center, Elekta (booth #725) ... Knife® Perfexion™ that promise to enhance information ... us the opportunity to demonstrate to neurological surgeons ...
... PITTSBURGH, April 13, 2012 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has received final approval from the U.S. ... Drug Application (ANDA) for Fluvastatin Capsules USP, 20 mg ... Lescol ® Capsules. This product is indicated for ...
Cached Medicine Technology:Elekta to Unveil New Neuroscience Solution for Leksell Gamma Knife at 2012 AANS Meeting 2Mylan Launches First Generic Version of Lescol® Capsules 2
(Date:5/3/2015)... 03, 2015 It is not too late to ... Walk in Memory of Lissa Anne Been in Arnold, Missouri ... great family-friendly event to honor her loving memory. It has benefited ... , Just having turned 37, Lissa suffered a brain aneurysm ... August 24, 2012. This event is designed to serve as a ...
(Date:5/2/2015)... 02, 2015 “ ActOn ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... connected with organizations to make a difference. , In this ... few things that aren’t about money, which is why those ...
(Date:5/2/2015)... Liverpool, Ohio (PRWEB) May 02, 2015 ... East Liverpool City Hospital (ELCH) gathered to celebrate improvements ... of River Valley Health Partners (RVHP), had zero acquired ... zero urinary catheter associated infections. ELCH was also recently ... , The management team at ELCH credited the teamwork ...
(Date:5/1/2015)... (PRWEB) May 02, 2015 IDLife LLC, ... is proud to announce the addition of its newest ... is a life long athlete, growing up in gymnastics ... after college by becoming a personal trainer and helping ... the face of several TV shows highlighting her stunning ...
(Date:5/1/2015)... Va. (PRWEB) May 01, 2015 The ... nation’s leading nonprofit authority on the use of health ... as a key contributing resource to the United States ... use of electronically readable cards in Medicare. The report, ... and Providers ” was released to the public on ...
Breaking Medicine News(10 mins):Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3
... New Single ... People to Sign Up to Donate Life - New CD - No Regrets In Stores ... Beverly Hills, ... smash with the song "I Swear," is returning to recording and performing after a seven-year ...
... , Prostitution research takes to the ... Aug. 25 Dallas prostitutes are getting a chance to ... Police Department, Dallas County Sheriff,s Office, Dallas County Commissioner,s Office, ... and Homeward Bound, which serves as the lead for more ...
... too little is known about these ,in situ, malignancies, experts ... of women with breast cancer in situ in the United States ... 2016 that number is expected to increase to more than 1 ... of newly diagnosed breast cancers. It is the early stage of ...
... , , SAN DIEGO, Aug. ... in the S&P 500 index following the company,s planned spinoff from Cardinal ... index on Sept. 1, coinciding with its first day of regular-way trading ... , "Our inclusion in the S&P 500 is a ...
... , TUESDAY, Aug. 25 (HealthDay News) -- In a major ... that saliva contains at least 50 microRNAs that could aid ... in the saliva of 50 people with oral squamous cell ... microRNAs that may be associated with oral cancer. , The ...
... long-term tamoxifen use among breast cancer survivors decreases their ... of second breast cancer, such use is associated with ... aggressive, difficult-to-treat type of cancer in the breast opposite, ... Christopher Li, M.D., Ph.D., and colleagues at Fred Hutchinson ...
Cached Medicine News:Health News:R&B / Pop Vocal Quartet All-4-One Makes 7-Year Comeback 2Health News:R&B / Pop Vocal Quartet All-4-One Makes 7-Year Comeback 3Health News:UNTHSC Collaborates With Law Enforcement to Provide Alternatives to Dallas Prostitutes 2Health News:UNTHSC Collaborates With Law Enforcement to Provide Alternatives to Dallas Prostitutes 3Health News:More Women Surviving After Early Breast Cancer 2Health News:More Women Surviving After Early Breast Cancer 3Health News:CareFusion Corp to be Included in S&P 500 Index 2Health News:Saliva May Help Spot Oral Cancer Early 2Health News:Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer 2
... basic Thermomixer is a compact model that ... x 1.5 ml tubes. Impressive features of ... design, and high stabilityeven at maximum mixing ... gentle to vigorous mixing, including intermittent mixing; ...
... ug Strept. 25 ug Fungizone ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
... 25,000 units Penicillin/25,000 ... Cell Culture Reagent and ... in accordance with cGMP ... culture tested to assure ...
Penicillin-Streptomycin-Glutamine (100X) liquid...
Medicine Products: